TWI749881B - 二氧代哌類衍生物、其製備方法及其在醫藥上的應用 - Google Patents

二氧代哌類衍生物、其製備方法及其在醫藥上的應用 Download PDF

Info

Publication number
TWI749881B
TWI749881B TW109140529A TW109140529A TWI749881B TW I749881 B TWI749881 B TW I749881B TW 109140529 A TW109140529 A TW 109140529A TW 109140529 A TW109140529 A TW 109140529A TW I749881 B TWI749881 B TW I749881B
Authority
TW
Taiwan
Prior art keywords
phenyl
chloro
tert
mmol
dioxopiper
Prior art date
Application number
TW109140529A
Other languages
English (en)
Chinese (zh)
Other versions
TW202120499A (zh
Inventor
俊軍 吳
陸銀鎖
肖瑛
王延彬
呂洋
邢偉
Original Assignee
大陸商深圳信立泰藥業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商深圳信立泰藥業股份有限公司 filed Critical 大陸商深圳信立泰藥業股份有限公司
Publication of TW202120499A publication Critical patent/TW202120499A/zh
Application granted granted Critical
Publication of TWI749881B publication Critical patent/TWI749881B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW109140529A 2019-11-21 2020-11-19 二氧代哌類衍生物、其製備方法及其在醫藥上的應用 TWI749881B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201911147949 2019-11-21
CN201911147949.3 2019-11-21

Publications (2)

Publication Number Publication Date
TW202120499A TW202120499A (zh) 2021-06-01
TWI749881B true TWI749881B (zh) 2021-12-11

Family

ID=75979946

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109140529A TWI749881B (zh) 2019-11-21 2020-11-19 二氧代哌類衍生物、其製備方法及其在醫藥上的應用

Country Status (3)

Country Link
CN (1) CN114728914B (fr)
TW (1) TWI749881B (fr)
WO (1) WO2021098817A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102026996A (zh) * 2008-03-13 2011-04-20 百时美施贵宝公司 作为凝血因子xia抑制剂的哒嗪衍生物
WO2018041122A1 (fr) * 2016-08-31 2018-03-08 江苏恒瑞医药股份有限公司 Dérivé d'oxopicolinamide, son procédé de préparation et son utilisation pharmaceutique
CN107793396A (zh) * 2016-08-31 2018-03-13 江苏恒瑞医药股份有限公司 环氧基取代的氧代吡啶类衍生物、其制备方法及其在医药上的应用
JP2019077704A (ja) * 2014-01-31 2019-05-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 芳香族p2’基を有する第xia因子阻害剤としてのマクロ環

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2124511C1 (ru) * 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
US20080221063A1 (en) * 2005-07-08 2008-09-11 Astrazeneca Ab Heterocyclic Sulfonamide Derivatives As Inhibitors Of Factor Xa
ES2595240T3 (es) * 2012-07-09 2016-12-28 Lupin Limited Derivados de tetrahidroquinazolinona como inhibidores de PARP

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102026996A (zh) * 2008-03-13 2011-04-20 百时美施贵宝公司 作为凝血因子xia抑制剂的哒嗪衍生物
JP2019077704A (ja) * 2014-01-31 2019-05-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 芳香族p2’基を有する第xia因子阻害剤としてのマクロ環
WO2018041122A1 (fr) * 2016-08-31 2018-03-08 江苏恒瑞医药股份有限公司 Dérivé d'oxopicolinamide, son procédé de préparation et son utilisation pharmaceutique
CN107793396A (zh) * 2016-08-31 2018-03-13 江苏恒瑞医药股份有限公司 环氧基取代的氧代吡啶类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
TW202120499A (zh) 2021-06-01
CN114728914B (zh) 2023-05-12
CN114728914A (zh) 2022-07-08
WO2021098817A1 (fr) 2021-05-27

Similar Documents

Publication Publication Date Title
US11046697B2 (en) Compounds and compositions useful for treating disorders related to NTRK
JP2021513534A (ja) 抗癌剤として有用なテトラヒドロキナゾリン誘導体
EP2588466B1 (fr) Dérivés de la 5-amino-3,6-dihydro-1H-pyrazin-2-one utiles en tant qu'inhibiteurs de la bêta-sécrétase (BACE)
RU2701156C2 (ru) Азотсодержащие гетероциклические производные и их применение в фармацевтических препаратах
EP3860989B1 (fr) Pyrrolines fusionnées qui agissent en tant qu'inhibiteurs de la protéase 30 (usp30) spécifique de l'ubiquitine
ES2800313T3 (es) Compuestos de heteroarilo bicíclico sustituidos
JP2018527329A (ja) Magl阻害薬としての1,1,1−トリフルオロ−3−ヒドロキシプロパン−2−イルカルバマート誘導体および1,1,1−トリフルオロ−4−ヒドロキシブタン−2−イルカルバマート誘導体
EP3632903B1 (fr) Composé tenant lieu de modificateur autophage, son procédé de préparation et son application
JP2022547952A (ja) Brd9二機能性分解誘導薬及びその使用方法
EP3707142B1 (fr) Dérivés de pyrrolopyrazine à utiliser en tant qu'inhibiteurs de l'intégrine alpha v
KR20210107046A (ko) 거대고리 화합물 및 질환 치료에서 이들의 용도
RU2747318C2 (ru) Производные аминопиридина и их применение в качестве селективных ингибиторов alk-2
WO2015178955A1 (fr) Composés éthynyle hétérobicycliques substitués en tant qu'inhibiteurs de la tyrosine kinase
WO2021113625A1 (fr) Composés et procédés de modulation de cd73 et leurs indications
CN104411696A (zh) 环己烷-1,2′-萘-1′,2″-咪唑化合物及其作为bace抑制剂的用途
KR20220106778A (ko) 간 x 수용체 작용제로서의 1,2,4-옥사디아졸 유도체
CA3225439A1 (fr) Inhibiteurs de cdk2 et leurs procedes d'utilisation
CN104394862A (zh) 色满化合物
TW201808908A (zh) 因子XIa抑制劑
US20180334436A1 (en) Tetrahydroisoquinoline derivatives
TWI749881B (zh) 二氧代哌類衍生物、其製備方法及其在醫藥上的應用
WO2021110076A1 (fr) Dérivés d'oxamide, leur procédé de préparation et leur utilisation en médecine
WO2022083706A1 (fr) Sels de composés inhibiteurs de fxia, leur procédé de préparation et leur utilisation pharmaceutique
TW200526642A (en) Heterocyclic derivatives
NL2031175B1 (en) Dhcr24 inhibitory compounds